"I am very happy to welcome Patrick Greatrex to CMC Contrast." says Magnus Corfitzen, CMC Contrast’s Chairman. “Patrick has a very strong business development background in both large and smaller life science companies. He has held a number of leading positions and has been involved in securing funding, acquiring and divesting companies, designing clinical trials, launching innovative products and driving sales activities. He joins CMC Contrast at a very exciting time as we begin our phase 3 trial and prepare for commercialisation.”
"I am truly excited to join CMC Contrast.” says Patrick Greatrex. “It is a privilege to work with a late stage drug development opportunity with convincing clinical data. The experienced Board and Management Team of CMC Contrast have set a clear strategy which is motivating. As we move into an exciting Phase 3 clinical development program, I look forward to strengthening our clinical development capabilities and working with the team at CMC Contrast in realising our vision.”
About CMC Contrast
CMC Contrast AB is a privately owned drug development company that specializes in developing targeted contrast media for Magnetic Resonance Imaging (MRI). CMC Contrast’s first product, CMC 001, is the world’s first oral contrast agent for MRI of the liver. CMC 001 is an oral manganese-based contrast which enables safe and excellent liver enhancement in MRI, without the risks associated with gadolinium based contrast media.
For further details please contact
Magnus Corfitzen
Chairman CMC Contrast AB
Sunstone Capital
Mobile: +45 4080 4863
Email: corfitzen@sunstonecapital.com
Patrick Greatrex
Chief Executive Office CMC Contrast AB
Mobile: +46 720 173 163
Email: pg@cmc-contrast.dk
